http://content.nejm.org/cgi/content/full/358/3/293
Are Incretin-acting drugs a worthwhile prescription for Type 2 Diabetes Mellitus?
Submitted by Anonymous on Mon, 2008-09-01 15:04- American Medical Association
- Anti-diabetic drugs
- Centers for Disease Control and Prevention
- Diabetes
- Diabetes mellitus type 2
- diabetes therapies
- Dipeptidyl peptidase-4 inhibitors
- Eli Lilly and Company
- Endocrine system
- Endocrinology
- Exenatide
- food
- Glucagon
- Health
- Health
- http://content.nejm.org/cgi/content/full/358/3/293
- http://www.medscape.com/viewarticle/559585_print
- http://www.novonordisk.com/investors/rd_pipeline/rd_pipeline.asp?showid=4
- Incretin
- Massachusetts
- Medicine
- Nauck
- New England Journal
- New England Journal of Medicine
- Novo Nordisk
- Peptide hormones
- pioglitazone
- rosiglitazone
- United States
- Vildagliptin
Type 2 Diabetes Mellitus (T2DM) is an epidemic and alarming metabolic disorder. The Centers for Disease Control and Prevention (CDC) estimated that in 2005 the prevalence of diabetes in the United States was 20.8 million. Diabetes is diagnosed in 14.6 million persons and undiagnosed in 6.2 million. T2DM is 90% to 95% of prevalent diabetes. About 41 million people in the United States are believed to have pre-diabetes. The main etiologic pathways of T2DM are insulin resistance and lack of compensatory insulin secretion.
»
- Read more
- 113 reads
